Page 2462 - Williams Hematology ( PDFDrive )

2433
2432 Index Index 2433

fibrinogen conversion to, 2152–2153, 2154f inhibitors, 2307–2308. See also Fibroplasia, 1322–1323, 1322t
formation, 2200 Antifibrinolytic therapy Fibrosis, marrow, 32
functions, 1933 plasminogen activator inhibitors. See Fibulins, 64
in inflammation, 2201 Plasminogen activator inhibitor Ficolin-1, 1013t, 1014
polymerization, 1933, 1933f (PAI)-1 Filamin, 1838–1839, 1838f, 1848
Fibrin degradation products, 2205–2206, serpins, 1145, 1958, 2304t, 2307–2308 Filamin A, 1832t, 1837, 1838, 2059
2205t thrombin-activatable fibrinolysis Filamin B, 1832t, 1838
Fibrin glue/sealant inhibitor. See Thrombin-activatable Filanesib, for myeloma, 1756
for hemophilia A, 2123 fibrinolysis inhibitor (TAFI) Filariasis, 957t
for inherited platelet disorders, 2062 phases, 2154 Filgrastim, for supportive therapy, 1243,
for superficial bleeds in fibrinogen plasmin in. See Plasmin 1247. See also Granulocyte colony-
abnormalities, 2159 plasminogen activators in. See stimulating factor (G-CSF)
for superficial wounds/dental extractions, Plasminogen activators Fimbrin (L-plastin), 1833t
2157 plasminogen in, 2303, 2303, 2304–2305t, FIPILI-PDGFR-α (FIFPLI-PDGFRA), 977,
Fibrinogen 2304f, 2304t 1469, 1470
activation, 1933, 1933f in pregnancy, 2312 FISH (fluorescence in situ hybridization),
characteristics, 1916t, 1932 vascular, 1972–1976 175t, 176, 176f, 1711
conversion to fibrin and network assembly, endothelial cells in, 1973–1974, 1973f Fish oils, 2079
2152–2153, 2153f in vascular disease, 1975–1976, 1975f Fish tapeworm, 601, 604
crosslinking by factor XIII, 2153 in vascular injury, 1974–1975, 1974t 5q-minus syndrome, 1312, 1347, 1347f
degradation, 2309–2310, 2310f Fibrinolytic activators, 1285 FIX, 441–442
in disseminated intravascular coagulation, Fibrinolytic proteins, 1973–1974, 1973f, FKBP51, 1322
2201 2304–2305t FKHD (forkhead transcription factors), 209
in fibrinolysis, 2154 Fibrinolytic therapy, 393, 402–403, 2312– FL. See Flt3 ligand (FL)
functions, 1933, 1979t 2317 FLAER (fluorescently labeled inactive variant
gene structure and variations, 1933, 1934f, agents for of protein aerolysin), 37–38
2151, 2154–2155 alteplase. See Alteplase FLAG-Ida regimen, for myelodysplastic
hereditary abnormalities comparison, 2313t syndromes, 1361
afibrinogenemia/hypofibrinogenemia. reteplase, 403, 2313t Flavopiridol
See Afibrinogenemia/ streptokinase. See Streptokinase for acute myelogenous leukemia, 218
hypofibrinogenemia tenecteplase. See Tenecteplase for chronic lymphocytic leukemia,
dysfibrinogenemia/ tissue-type plasminogen activator, 403, 1539
hypodysfibrinogenemia. 2277 FLCs (free light chains), 1708, 1714, 1741,
See Dysfibrinogenemia/ bleeding complications, 2304t, 2317t 1742f, 1775, 1781. See also
hypodysfibrinogenemia for myocardial infarction, 2295 Immunoglobulin (Ig) light chains
integrin α β and, 1854 patient selection, 2313t FLI1, 2060, 2061
IIb 3
interactions, 1846t for peripheral vascular disease, 2316–2317 c-FLIP, 207
in platelets, 1845 platelet effects, 1855t, 2078 Flippases, 662, 742
structure, 1846t, 1932, 1933f, 2151, 2152f principles of, 2313 FLIP proteins, 207
synthesis, 2152 for stroke. See Stroke, fibrinolytic therapy FLJ9586. See TSSC6
Fibrinogen concentrates, 2136t, 2156–2157 for FLJ17158. See TSSC6
Fibrinogen-like protein 2 (FGL2), 1182 for venous thromboembolism, 2277–2278 FLK-1, 258
Fibrinogen receptor. See Integrin α β Fibrinopeptide release, 2153, 2158 Floppases, 662
IIb 3
Fibrinolysins, 2307 Fibrin tissue adhesive, for hemophilia A, Flow cytometry, 35–37, 36f, 1715, 1716
Fibrinolysis 2123 Floxuridine, megaloblastic anemia and, 606t
angiogenesis and, 2311 Fibroblast-growth factor-4, 1817 Flt1 (fms-like tyrosine kinase-1), 2011
in antiphospholipid syndrome, 2237 Fibroblasts, 264 FLT3, 1155
basic concepts, 2303, 2304f Fibronectin, 62–63 FLT3
cellular receptors, 2308–2309 in hematopoietic stem cells, 261, 266 in acute myelogenous leukemia, 181, 181t,
in coagulation, 1942 in inflammation, 283 198, 226t, 363, 1377, 1378t, 1383,
deficiency, thrombosis and, 2310–2311 interactions, 1846t 1415
developmental regulation, 2312 macrophages and, 1054 in acute promyelocytic leukemia, 1391
in disseminated intravascular coagulation, in newborn, 106 in B-cell acute lymphoblastic leukemia,
2202–2203 in platelets, 1845, 1865 232t
enhanced, 2312 structure, 1846t detecting mutations in, 163, 1415
in hepatic disease, 2192 Fibronectin receptor. See Integrin α β Flt3 (CD135), 309
5 1

Kaushansky_index_p2393-2506.indd 2433 9/21/15 3:21 PM